Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PM-014 is a standardized **botanical herbal extract** derived from the traditional Korean medicine formula Chung-Sang-Bo-Ha-Tang and simplified from the original 18-herb prescription to a 7-herb formulation to improve reproducibility and standardization. It has been investigated primarily in academic Korean medicine research for inflammatory and fibrotic respiratory disorders, including chronic obstructive pulmonary disease, radiation-induced pneumonitis and pulmonary fibrosis, and particulate matter-induced lung inflammation. The available literature supports a **broad anti-inflammatory and immunomodulatory mechanism** rather than a single defined molecular target, with reported suppression of inflammatory cell recruitment into the lung and reduction of pro-inflammatory cytokines such as TNF-α and IL-6. No clear commercial brand name, approved product status, or single pharmaceutical company sponsor is evident from the provided context.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PM-014.